ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

KINERET
Arthritis/rheumatic disorders
Miscellaneous immune disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

KINERET Rx

Generic Name and Formulations:
Anakinra 100mg/0.67mL; soln for SC inj; preservative-free.

Company:
Sobi, Inc.

Therapeutic Use:

Indications for KINERET:

To reduce signs/symptoms and slow progression of structural damage in moderately to severely active rheumatoid arthritis (RA) that failed DMARD(s), as monotherapy or with DMARDs other than TNF blockers.

Adult:

≥18yrs: 100mg SC once daily. Severe renal impairment or ESRD (CrCl <30mL/min): may consider every other day dosing.

Children:

<18yrs: not recommended.

Contraindications:

Hypersensitivity to E. coli-derived proteins.

Warnings/Precautions:

Increased risk of serious infections; discontinue if develop in RA patients; consider risk vs. benefit in NOMID patients. Active infections: do not initiate. Chronic infections (eg, tuberculosis). Asthma. Immunosuppression. Malignancies. Discontinue if severe hypersensitivity reaction occurs. Monitor neutrophil count at baseline, monthly for first 3 months, then every 3 months for up to 1 year. Renal or hepatic impairment. Elderly. Pregnancy (Cat.B). Nursing mothers.

Interactions:

Concomitant TNF blockers; not recommended. Avoid concurrent live vaccines.

Pharmacological Class:

Interleukin-1 (IL-1) blocker.

Adverse Reactions:

Inj site reactions, upper RTI, headache, nausea, diarrhea, sinusitis, arthralgia, flu-like symptoms, abdominal pain; infections, neutropenia.

How Supplied:

Single-dose syringe—7, 28

Indications for KINERET:

Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).

Adult:

≥18yrs: not applicable.

Children:

<18yrs: Initially 1–2mg/kg SC daily; may adjust by increments of 0.5–1mg/kg; max 8mg/kg/day. Usually give once daily, but dose may be split into twice daily administration. Severe renal impairment or ESRD (CrCl <30mL/min): may consider every other day dosing.

Contraindications:

Hypersensitivity to E. coli-derived proteins.

Warnings/Precautions:

Increased risk of serious infections; discontinue if develop in RA patients; consider risk vs. benefit in NOMID patients. Active infections: do not initiate. Chronic infections (eg, tuberculosis). Asthma. Immunosuppression. Malignancies. Discontinue if severe hypersensitivity reaction occurs. Monitor neutrophil count at baseline, monthly for first 3 months, then every 3 months for up to 1 year. Renal or hepatic impairment. Elderly. Pregnancy (Cat.B). Nursing mothers.

Interactions:

Concomitant TNF blockers; not recommended. Avoid concurrent live vaccines.

Pharmacological Class:

Interleukin-1 (IL-1) blocker.

Adverse Reactions:

Inj site reactions, upper RTI, headache, nausea, diarrhea, sinusitis, arthralgia, flu-like symptoms, abdominal pain; infections, neutropenia.

How Supplied:

Single-dose syringe—7, 28

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs